Limited immunological recognition of critical malaria vaccine candidate antigens
- PMID: 2902690
- DOI: 10.1126/science.2902690
Limited immunological recognition of critical malaria vaccine candidate antigens
Abstract
Current vaccine development strategies for malaria depend on widespread immunological responsiveness to candidate antigens such as the zygote surface antigens and the sporozoite coat protein, the circumsporozoite (CS) protein. Since immunological responsiveness is controlled mainly by genes mapping within the major histocompatibility complex (MHC), the humoral immune response to the zygote surface antigens and the cytotoxic T lymphocyte (CTL) response to the CS protein were examined in MHC-disparate congenic mouse strains. Only two of six strains responded to the 230-kilodalton zygote surface antigen and another two strains responded to the 48/45-kilodalton surface antigen. From two mouse strains, expressing between them five different class I MHC molecules, there was recognition of only a single CTL epitope from the CS protein, which was from a polymorphic segment of the molecule. The restricted CTL response to this protein parallels the restricted antibody response to this protein observed in humans and mice. These findings suggest that subunit malaria vaccines now being developed may be ineffective.
Similar articles
-
Evidence implicating MHC genes in the immunological nonresponsiveness to the Plasmodium falciparum CS protein.Bull World Health Organ. 1990;68 Suppl(Suppl):80-4. Bull World Health Organ. 1990. PMID: 1709836 Free PMC article.
-
Sporozoite malaria vaccine. Where do we stand?Ann Parasitol Hum Comp. 1990;65 Suppl 1:49-52. doi: 10.1051/parasite/1990651049. Ann Parasitol Hum Comp. 1990. PMID: 1702271 Review.
-
Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.J Exp Med. 1995 Nov 1;182(5):1435-45. doi: 10.1084/jem.182.5.1435. J Exp Med. 1995. PMID: 7595214 Free PMC article.
-
T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine.Proc Natl Acad Sci U S A. 1988 Aug;85(15):5659-63. doi: 10.1073/pnas.85.15.5659. Proc Natl Acad Sci U S A. 1988. PMID: 2456577 Free PMC article.
-
Plasmodium falciparum CS protein--prime malaria vaccine candidate: definition of the human CTL domain and analysis of its variation.Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:241-7. doi: 10.1590/s0074-02761992000700040. Mem Inst Oswaldo Cruz. 1992. PMID: 1285314 Review.
Cited by
-
Distinct H-2 complex control of mortality, and immune responses to tuberculosis infection in virgin and BCG-vaccinated mice.Clin Exp Immunol. 1993 Nov;94(2):322-9. doi: 10.1111/j.1365-2249.1993.tb03451.x. Clin Exp Immunol. 1993. PMID: 8222323 Free PMC article.
-
Vaccinia virus vectors: new strategies for producing recombinant vaccines.Clin Microbiol Rev. 1990 Apr;3(2):153-70. doi: 10.1128/CMR.3.2.153. Clin Microbiol Rev. 1990. PMID: 2187593 Free PMC article. Review.
-
Where are we in the quest for vaccines for malaria?Drugs. 1991 Jan;41(1):1-10. doi: 10.2165/00003495-199141010-00001. Drugs. 1991. PMID: 1706981 Review. No abstract available.
-
Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens.J Exp Med. 1992 Nov 1;176(5):1483-7. doi: 10.1084/jem.176.5.1483. J Exp Med. 1992. PMID: 1383389 Free PMC article.
-
Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.Infect Immun. 2009 Oct;77(10):4502-9. doi: 10.1128/IAI.00442-09. Epub 2009 Aug 3. Infect Immun. 2009. PMID: 19651872 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials